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DOI 10.1016/j.ccr.2011.05.011SUMMARYPancreatic acinar cells of adult mice (RP60) are resistant to transformation by some of themost robust onco-
genic insults including expression of K-Ras oncogenes and loss of p16Ink4a/p19Arf or Trp53 tumor suppres-
sors. Yet, these acinar cells yield pancreatic intraepithelial neoplasias (mPanIN) and ductal adenocarcinomas
(mPDAC) if exposed to limited bouts of non-acute pancreatitis, providing they harbor K-Ras oncogenes.
Pancreatitis contributes to tumor progression by abrogating the senescence barrier characteristic of
low-grade mPanINs. Attenuation of pancreatitis-induced inflammation also accelerates tissue repair and
thwarts mPanIN expansion. Patients with chronic pancreatitis display senescent PanINs, providing they
have received antiinflammatory drugs. These results support the concept that antiinflammatory treatment
of people diagnosed with pancreatitis may reduce their risk of developing PDAC.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one of the tumors
with worst prognosis, with <5%of patients surviving 5 years after
diagnosis. During the last few years there have been important
advances in our understanding of the molecular events respon-
sible for the development of PDAC (Jones et al., 2008; Hruban
and Adsay, 2009). Yet, progress in prevention, early diagnosis
and therapeutic treatment of PDAC has not experienced major
advances (Hidalgo, 2010).
The development of geneticallymodifiedmouse tumormodels
of PDAC offers the possibility to replicate in experimental
systems the multiple events that lead to this complex disease
(Hingorani et al., 2003; Guerra et al., 2007). In these models, in-
ducible expression of a resident K-Ras oncogene during embry-Significance
Pancreatic ductal adenocarcinoma (PDAC) is one of the tumor t
and early development may help to save lives. Here we report
lead to mPDAC as long as the acinar cells express K-Ras on
induce mPDAC providing that the inflammatory response has
inating the senescence program characteristic of benign lesion
senescence markers but only if they have received antiinflamm
diagnosed with even mild bouts of pancreatitis may prevent, o
728 Cancer Cell 19, 728–739, June 14, 2011 ª2011 Elsevier Inc.onic development triggers preneoplastic pancreatic intraepithe-
lial lesions (mPanINs), which can progress into invasive mPDAC.
Addition of other mutations observed in human PDAC, including
inactivation of the P16INK4A/P19ARF, TRP53, or SMAD4 tumor
suppressors as well as activation of the HEDGEHOG signaling
pathway, significantly accelerate tumor development leading
to acquisition of a metastatic phenotype (Aguirre et al., 2003;
Hingorani et al., 2005; Bardeesy et al., 2006; Ijichi et al., 2006;
Pasca di Magliano et al., 2006).
Human PDAC is likely to originate from somatic mutations
in K-RAS during adulthood rather than during embryonic
development. We have previously shown that activation of
a resident K-Ras oncogene in adult mice does not induce
mPanINs and mPDAC (Guerra et al., 2007). Recently, it has
been shown that rat adult acinar cells are also refractory toypes with worst prognosis. Efforts to understand its etiology
that brief bouts of asymptomatic pancreatitis in adult mice
cogenes. K-Ras mutations occurring after pancreatitis also
not subsided. Inflammation contributes to mPDAC by elim-
s. Samples obtained from pancreatitis patients also display
atory therapy. Thus, antiinflammatory treatment of patients
r at least reduce the risk of developing PDAC.
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Pancreatitis Inhibits Oncogene-Induced Senescencetransformation by Ras oncogenes (Tanaka et al., 2010). The
resistance of adult acinar cells to K-Ras oncogenes may stem
from the exhaustion of permissive acinar progenitors or from
intrinsic changes in the biology of acinar cells during adulthood.
In this study, we have examined whether the resistance of
adult acinar cells to malignant transformation by K-Ras onco-
genes may result from the existence of a proliferative and/or
senescence barrier mediated by p16Ink4a, a gene frequently in-
activated in human PDAC, or by other tumor suppressors also
implicated in PDAC development such as Trp53 (Collado et al.,
2005). In addition, we have examined whether limited episodes
of pancreatitis may cooperate with K-Ras oncogenes to induce
mPDAC and have unveiled some of the mechanisms by which
pancreatitis contributes to mPanIN development. Finally, we
have extended these observations to human biopsies obtained
from pancreatitis and PDAC patients.
RESULTS
Adult Acinar Cells Are Resistant to Multiple Oncogenic
Insults
Expression of an endogenous K-Ras oncogene in acinar cells of
K-Ras+/LSLG12Vgeo mice (designated from nowon as K-Ras+/G12V)
during late embryonic development (E16.5) leads to the genera-
tion of acinar-to-ductal metaplasias followed by the appearance
of low and high-grade mPanINs that occasionally progress to
mPDAC (Guerra et al., 2007). The neoplastic nature of these
lesions has been validated by other investigators (Hruban
et al., 2006). The percentage of K-RasG12V-expressing acinar
cells susceptible of inducing mPanIN lesions become signifi-
cantly reduced during early postnatal development (see Fig-
ure S1A available online). In agreement with other laboratories
(Gidekel Friedlander et al., 2009; Morris et al., 2010), induction
of K-RasG12V expression at 3 (P21) and 6 (P42) weeks of age
resulted in progressive reduction in the number of mice that
developed mPanINs and to a significant delay in the onset of
mPDAC. Acinar cells become resistant to mPanIN development
whenmice become 2months old (P60) (Figure S1). Other groups
have described frequent mPanIN induction on expression of
K-Ras oncogenes in acinar cells of 6-week-old mice (De La O
et al., 2008; Habbe et al., 2008). Although the bases for these
variations are unknown, it is possible that genetic background
may determine the precise timing at which postnatal acinar cells
become resistant to transformation by K-Ras oncogenes.
Next, we examined whether this resistance could be over-
come by inactivation of the oncogene-induced senescence
(OIS) barrier likely to be mediated by tumor suppressors
such as p16Ink4a/p19Arf or Trp53 (Collado and Serrano,
2010). Compound K-Ras+/G12V;Elas-tTA/tetO-Cre;p16Ink4a/
p19Arflox/lox (n = 13) and K-Ras+/G12V;Trp53lox/lox;Elas-tTA/
tetO-Cre (n = 7) mice were exposed to doxycycline from
conception until P60 to prevent expression of the Elastase-
driven Cre recombinase. Removal of doxycycline from the
drinking water allowed K-RasG12V expression in adult acinar cells
along with concomitant ablation of the p16Ink4a/p19Arf lox and
Trp53lox conditional alleles, respectively (Figures 1A and 1B).
Mice were examined for the presence of pancreatic lesions 6
and 12 months after removal of doxycycline. Surprisingly, none
of the pancreata presented detectable lesions including meta-plasias or low-grade mPanINs in spite of serial analysis of the
entire organ (Figures 1A and 1B). Excision of the conditional
p16Ink4a/p19Arflox and Trp53lox alleles in K-RasG12V-expressing
acinar cells was confirmed by PCR analysis of DNA extracted
from b-galactosidase expressing cells, the surrogate marker
for K-RasG12V expression (Guerra et al., 2007), with the help of
a laser-capture microscope (Figures S1B and S1C). These
observations indicate that adult acinar cells are extremely
resistant to malignant transformation and can tolerate some of
the most robust genetic insults responsible for neoplastic
development.
Loss of p16Ink4a/p19Arf and Trp53 in Adult Acinar Cells
Only Contribute to mPanIN and mPDAC Development in
the Presence of K-Ras Oncogenes
In addition to K-RAS mutations, most human PanINs display
inactivation of the P16INK4a/P14ARF locus. Thus, we examined
whether pancreatitis may also cooperate with loss of these
tumor suppressors to initiate mPanIN formation in the absence
of K-Ras mutations. We induced pancreatitis by treating mice
with daily doses of caerulein, a decapeptide analog of the
pancreatic secretagogue cholecystokinin, as previously
described (Guerra et al., 2007). K-Ras+/+;p16Ink4a/p19Arflox/lox;
Elas-tTA/tetO-Cre mice exposed to doxycycline until P60 were
treated with caerulein and examined at 14 months of age.
Systematic analysis of their pancreata (n = 8) by serial sectioning
failed to reveal any mPanINs (Figures 1C and 1D). Because
TRP53 is also lost in many human PDACs, we examined whether
pancreatitis cooperated with loss of this tumor suppressor to
induce mPanIN formation in adult mice. K-Ras+/+;Trp53lox/lox;
Elas-tTA/tetO-Cre mice (n = 4) exposed to doxycycline until
P60 and treated with caerulein also failed to display mPanINs
in spite of serially sectioning of all pancreata (Figures 1C and
1D). As expected, control K-Ras+/G12V;Elas-tTA/tetO-Cre mice
(8/8) submitted to the same treatments developed abundant
low and high-grade mPanINs (data not shown). These observa-
tions indicate that activation of K-Ras oncogenes is an essential
event to initiate mPanIN formation that cannot be replaced by
loss of either p16Ink4a/p19Arf or Trp53 tumor suppressors.
Loss of the p16Ink4a/p19Arf tumor suppressors in early
pancreatic precursors during embryonic development efficiently
cooperated with K-Ras oncogenes to induce invasive and meta-
static mPDAC (Aguirre et al., 2003). Activation of K-Ras onco-
genes along with concomitant loss of p16Ink4a/p19Arf in embry-
onic acinar cells also resulted in anaplastic carcinomas that
metastasized to liver, stomach, diaphragm, lung, lymph nodes
and spleen (Figures 2D and 2E). Thus, we examined whether
loss of p16Ink4a/p19Arf could cooperate with K-RasG12V in adult
mice. P90 K-Ras+/G12V;p16Ink4a/p19Arflox/lox;Elas-tTA/tetO-Cre
mice exposed to doxycycline until P60 were treated with caeru-
lein to induce pancreatitis. As illustrated in Figure 2A, the lifespan
of these mice was considerably shortened compared to mice
that retained the p16Ink4a/p19Arf locus. Survival of heterozy-
gous p16Ink4a/p19Arf+/lox mice was similar to that of wild-type
controls (data not shown). After 3 months of caerulein treatment,
the number of low-grade mPanINs did not differ significantly
between p16Ink4a/p19Arf wild-type, heterozygous, or null
mice (Figures 2B and 2C). However, the latter contained more
high-grade lesions and developed mPDAC (Figures 2B and 2C;Cancer Cell 19, 728–739, June 14, 2011 ª2011 Elsevier Inc. 729
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Figure 1. Loss of p16Ink4a/p19Arf or Trp53 Tumor
Suppressors Only Contribute to mPanIN and mPDAC
Development in the Presence of K-Ras Oncogenes and
Pancreatitis
(A) K-Ras+/G12V;p16Ink4a/p19Arflox/lox;Elas-tTA/tetO-Cre and
K-Ras+/G12V;Trp53lox/lox;Elas-tTA/tetO-Cre mice were exposed to
doxycycline (Dox, thin line) until P60. At this time, doxycycline was
removed from the drinking water to allow expression of the
K-RasG12V oncogene and to ablate the p16Ink4a/p19Arf and the
Trp53 tumor suppressors in adult acinar cells.
(B) Hematoxylin and eosin (H&E) staining of paraffin sections
obtained from 14-month-old (left) K-Ras+/G12V;p16Ink4a/
p19Arf lox/lox;Elas-tTA/tetO-Cre mice and (right) K-Ras+/G12V;
Trp53lox/lox;Elas-tTA/tetO-Cre mice shows normal parenchyma
with no mPanIN lesions 1 year after turning on K-RasG12V
expression and ablating the p16Ink4a/p19Arf and the Trp53 tumor
suppressors. i, islets; d, normal ducts. Scale bar represents 50 mm.
(C) K-Ras+/+;p16Ink4a/p19Arflox/lox;Elas-tTA/tetO-Cre and
K-Ras+/+;Trp53lox/lox;Elas-tTA/tetO-Cre mice were exposed to
doxycycline (Dox, thin line) until P60. At this time, doxycycline was
removed from the drinking water to allow ablation of the p16Ink4a/
p19Arf and the Trp53 tumor suppressors in adult acinar cells. Mice
were subsequently treated with caerulein for three months (P90-
P180) (gray box).
(D) H&E staining of paraffin sections obtained from 14-month-old
(left) K-Ras+/+;p16Ink4a/p19Arflox/lox;Elas-tTA/tetO-Cre mice and
(right) K-Ras+/+;Trp53lox/lox;Elas-tTA/tetO-Cre mice shows normal
parenchyma with no mPanIN lesions 8 months after finishing
caerulein treatment. i, islets; d, normal duct. Scale bar represents
50 mm.
See also Figure S1.
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Pancreatitis Inhibits Oncogene-Induced SenescenceFigures S2A–S2H). Analysis of these tumors at humane end point
revealed that many of these mPDAC (Figures S2I–S2L) had also
metastasized to liver and diaphragm (Figures S2M–S2P). More-
over, we also observed an occasional sarcomatoid tumor when
mice were sacrificed at humane end point (data not shown).
These observations indicate that loss of p16Ink4a/p19Arf
contributes to pancreatic cancer in adult mice, providing that
the mice express K-Ras oncogenes and have suffered from
pancreatitis.
Episodic Pancreatitis Is Sufficient to Induce mPanINs
and mPDAC in K-RasG12V Expressing Adult Acinar Cells
Chronic pancreatitis is one of the highest risk factors for the
development of PDAC in humans (Lowenfels et al., 1993; Malka
et al., 2002). In adult mice (pR 60), chronic pancreatitis is essen-730 Cancer Cell 19, 728–739, June 14, 2011 ª2011 Elsevier Inc.tial to induce mPanIN lesions and mPDAC in acinar
cells expressing a resident K-RasG12V oncogene
(Guerra et al., 2007). Yet, it is not known whether short
episodes of pancreatitis may also represent a risk for
PDAC development. To explore this possibility, we
exposed adult (P90) K-Ras+/G12V;Elas-tTA/tetO-Cre
mice to caerulein for 3 months, 30 days after turning
on K-RasG12V expression. This treatment had no
detectable consequences on the overall health of the
animals. In spite of its asymptomatic nature, this treat-
ment led to significant atrophy in the parenchyma
including mucinous metaplasia, edema and fibrosis
regardless of whether the mice expressed a K-Rasoncogene (Figure S3A). In addition, all animals exhibited an
inflammatory response throughout the entire parenchyma,
primarily made up of macrophages and T lymphocytes (data
not shown). At 8 months of age, 2 months after cessation of
the caerulein treatment, all K-Ras+/G12V;Elas-tTA/tetO-Cre mice
(n = 15), but not control K-Ras+/+;Elas-tTA/tetO-Cre animals
(n = 7), displayed low and high-grademPanIN lesions (Figure 3A).
At this time, the pancreata of control mice showed limited
improvement of atrophic areas and decreased numbers of
inflammatory cells. Mutant mice, however, displayed increased
atrophy and fibrosis, whose levels were directly related to the
number and extent of the mPanIN lesions (data not shown). In
these mutant mice, the inflammatory cells, mainly macrophages
and T lymphocytes, were abundant and closely associated with
mPanIN lesions (Figure 4B).
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Figure 2. Loss of p16Ink4a/p19Arf Tumor Suppres-
sors Accelerates mPanIN and mPDAC Develop-
ment and Induces Anaplastic Sarcomatoid Tumors
(A) Survival of (solid circles) K-Ras+/G12V;p16Ink4a
/p19Arflox/lox;Elas-tTA/tetO-Cre and (open circles)
K-Ras+/G12V;p16Ink4a/p19Arf+/+;Elas-tTA/tetO-Cre mice
exposed to doxycycline until P60. At this time, doxycycline
was removed from the drinking water to activate
K-RasG12V expression and to ablate the p16Ink4a/p13Arf
tumor suppressors. Caerulein treatment started at P90.
(B) Average number of mPanIN1, mPanIN2/3 and
mPDAC lesions displayed at 6 months of age by (solid
bars) K-Ras+/G12V;p16Ink4a/p19Arflox/lox;Elas-tTA/tetO-
Cre (n = 5), (gray bars) K-Ras+/G12V;p16Ink4a/p19Arf+/lox;
Elas-tTA/tetO-Cre (n = 4) and (open bars)
K-Ras+/G12V;p16Ink4a/p19Arf+/+;Elas-tTA/tetO-Cre (n = 5)
mice treated as described in (A). Data shown represent
mean ± SD. **p < 0.01.
(C) H&E stained paraffin sections depicting representative
(left) low-grade mPanIN1, (middle) high-grade
mPanIN3, and (right) mPDAC lesions observed in
the K-Ras+/G12V;p16Ink4a/p19Arflox/lox;Elas-tTA/tetO-Cre
mice described in (B). The scale bars represent (left and
center) 20 mm and (right) 50 mm.
See also Figure S2.
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Pancreatitis Inhibits Oncogene-Induced SenescenceWhen control K-Ras+/+;Elas-tTA/tetO-Cre mice (n = 15) were
examined 6 months later, their pancreata had recovered almost
completely andweonlyobserved fewareasof inflammatory cells.
K-RasG12V-expressing pancreata had also recovered except for
areas of atrophy intimately associated with the mPanIN lesions.
The levels of inflammatory cells had also subsided except for
those closely associated with the mPanIN lesions (data not
shown). At this time, all mice displayed low and high-grade
mPanIN lesions (Figure 3A; Figure S3B). Moreover, 3 of the 15
K-Ras+/G12V;Elas-tTA/tetO-Cre animals had developed mPDAC,E0 P0 2 4 6 8 10 12 14 16 18 20
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mPDAC (0/15)of which two showed invasion of the proximal parenchyma and
one displayed metastasis in liver and lung (Figure 3A; Figures
S3C–S3I). ThesemPDACs displayed high levels of stroma similar
to those observed in human patients (Figures S3C and S3D). In
these lesions, inflammatory cells persisted but were located in
the periphery of the stroma that surrounded the glandular struc-
tures of the tumor (Figure 4C; Figure S3F).
Next, we reduced the time of caerulein exposure to 1 month
(Figure 3B). This shorter treatment also induced parenchyma
atrophy and recruitment of inflammatory cells, although the22 24
Months
mPanIN1 (10/10)
mPanIN2/3  (8/10)
mPDAC       (2/10)
Figure 3. Episodic Pancreatitis Induces
mPanINs and mPDAC in K-Ras+/G12V;Elas-
tTA/tetO-Cre Mice
K-Ras+/G12V;Elas-tTA/tetO-Cre mice were
exposed to doxycycline (thin line) and caerulein
(gray box) for the indicated periods of time. The
open box indicates the time of K-RasG12V
expression. The number of animals positive for
low-grade mPanIN1, high-grade mPanIN2/3, and
mPDAC is indicated for each protocol and time
point.
(A) Mice exposed to doxycycline (Dox) from
conception (E0) to P60 were treated with caerulein
(Caerul) for 3months, fromP90 to P180.Micewere
sacrificed at 8 and 14 months of age, that is 6 and
12 months after turning on K-RasG12V expression.
(B) Mice exposed to doxycycline from conception
(E0) to P60were treatedwith caerulein for 1month,
from P90 to P120. Mice were sacrificed at 8 and
14 months of age, that is 6 and 12 months after
turning on K-RasG12V expression.
(C) Mice exposed to doxycycline from conception
(E0) to P150 were treated with caerulein for
3 months, from P30 to P120. Mice were sacrificed
at 11, 17, and 23 months of age, that is, 6, 12, and
18 months after turning on K-RasG12V expression.
See also Figure S3.
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Figure 4. Inflammatory Infiltrates in mPanIN
Lesions and mPDAC in K-RasG12V Expressing Adult
Mice Treated with Caerulein for Three Months
(A) K-Ras+/G12V;Elas-tTA/tetO-Cre mice were exposed to
doxycycline (thin line) and caerulein (gray box) for the
indicated periods of time. Expression of the K-RasG12V
oncogene (open box) is indicated. Mice were sacrificed at 8
and 14 month of age.
(B and C) Immunostaining of inflammatory cells
surrounding (B) mPanIN lesions in 8-month-old-mice
(2 months after cessation of caerulein) and (C) mPDAC in
14-month-old-mice (8 months after cessation of caerulein
treatment) using antibodies against T lymphocytes (CD3
antibodies), B lymphocytes (Pax5 antibodies), macro-
phages (F4/80 antibodies), and neutrophils (MPO anti-
bodies). Insets show detailed areas containing the corre-
sponding immune cells. Scale bars represent 50 mm.
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Pancreatitis Inhibits Oncogene-Induced Senescenceextent of atrophic areas and inflammatory foci were signifi-
cantly reduced (data not shown). When mice were analyzed
at 8 months of age, 4 months after cessation of caerulein expo-
sure, >50% of the mice (5/9) had developed low-grade mPa-
nINs and three of them displayed high-grade lesions (Figure 3B;
Figure S3J). At this time, the parenchyma was well preserved
with few mucinous metaplasia and small focal areas of inflam-
matory cells, mostly associated with mPanIN lesions (data not
shown). Analysis of K-Ras+/G12V;Elas-tTA/tetO-Cre mice at
14 months of age revealed a similar percentage of animals
with high-grade mPanINs (3/8) (Figure 3B; Figure S3J).
However, none of them had developed mPDAC at this time.
When we allowed these mice (n = 11) to age (1.5 and 3 years
of age), we observed mPanIN lesions in most of them (10.2 ±
5.1 low-grade and 4.8 ± 2.6 high-grade mPanINs/mouse,
respectively) with only one mouse failing to show any lesions.
Yet, only two mice developed mPDAC (Figures S3K–S3N).
These observations indicate that development of high-grade732 Cancer Cell 19, 728–739, June 14, 2011 ª2011 Elsevier Inc.mPanIN and mPDAC in adult mice depends
on the extent of tissue damage and the inflam-
matory response.
We also interrogated whether PDAC develop-
ment required the presence of K-Ras oncogenes
at the time of pancreatic damage. To this end,
K-Ras+/G12V;Elas-tTA/tetO-Cre mice were main-
tained in doxycycline until P150 while they were
treated with caerulein from P30 to P120. Thus,
mice had 1month to recover fromcaerulein treat-
ment before expressing their resident K-RasG12V
oncogene (Figure3C). Analysis of 10pancreata at
6 months after turning on K-RasG12V expression
(11 months of age) revealed the presence of
mPanINs in fewmice (Figure 3C). Sixmonths later
(17 months of age), the percentage of mice
depicting mPanINs had increased to 50% (4/8)
(Figure 3C). All animals (n = 10) displayed
mPanINs on 18 months of continuous K-RasG12V
expression (23 months of age) (Figure 3C; Fig-
ure S3O), and two of them had mPDACs that
invaded the adjacent parenchyma (Figure 3C;
Figure S3P). No lesions were observed whenK-RasG12V expressionwasactivated at P150 inmice not exposed
to caerulein (Figure S1A). These observations indicate that K-Ras
oncogenes can initiate mPanIN and mPDAC development in
adult mice providing that there is preexisting pancreatic damage
and an inflammatory response.
Pancreatitis induces expression of genes characteristic of
progenitor cells such as Pdx1 (Jensen et al., 2005; Fendrich
et al., 2008) and Sox9 (Seymour et al., 2007; Yoshida et al.,
2008), hence raising the possibility that the susceptibility to
K-Ras oncogenic signaling might be due to the induction of
a less mature differentiated state. As illustrated in Figure S3Q,
caerulein treatment induces high levels of Pdx1 and Sox9 in acini
as well as in metaplasias. However, Pdx1 expression faded away
from the acinar cells within 30 days after caerulein withdrawal
and was not expressed (except in very few cells) at the time
(P150) when K-RasG12V expression was turned on (Figure S3Q).
As previously reported, Pdx1 becomes reexpressed in low-grade
mPanINs (Hingorani et al., 2003; Guerra et al., 2007; Morris et al.,
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Figure 5. Senescence Markers Are a Feature of Low-
Grade mPanINs, but Disappear in High-Grade mPanIN2/
3 and mPDAC
(A–C) Senescence associated b-galactosidase (SA-b-Gal) staining
(blue) in (A) low-grade mPanIN1 but not in (B) high-grade
mPanIN2/3 or (C) mPDAC.
(D–F) p16Ink4a immunostaining (brown) in (D) low-grade mPanIN1
but not in (E) high-grade mPanIN2/3 or (F) mPDAC.
(G–I) Ki67 immunostaining (brown) inversely correlates with the
expression of the above senescence markers. Ki67 is detected in
a low percentage of cells of low-grade mPanIN1 (G) and in a high
percentage of cells of high-grade mPanIN2/3 (H) and mPDAC (I).
Note that (D–G), (E–H), and (F–I) correspond to serial sections.
Scale bar represents 50 mm.
See also Figure S4.
Cancer Cell
Pancreatitis Inhibits Oncogene-Induced Senescence2010). Instead, Sox9 expression was maintained throughout the
transformation process including metaplasias (Figure S3Q) and
mPanINs (Morris et al., 2010). As expected, the expression pattern
of acinar cell markers such as chymotrypsin and elastase was
retained at the time of K-RasG12V expression as well as after a
month of continuous oncogene expression (Figure S3Q).
The inflammatory response observed immediately after
cessation of caerulein exposure (P120) (Figure S3R) significantly
subsided 30 days later in both in wild-type andmutant mice (Fig-
ure S3S) at a time, P150, in which induction of K-RasG12V expres-
sion has not yet taken place (Figure 3C; Figure S3Q). At this time,
we could only observe the presence of T lymphocytes (Fig-
ure S3S). Occasionally, isolated B lymphocytes, macrophages
and neutrophils were also observed (Figure S3S). At P180, that
is 30 days after turning on K-RasG12V expression, the inflamma-
tory response remained at similar levels and no significant differ-
ences were observed between wild-type and mutant mice (Fig-
ure S3T). No mPanIN lesions were observed at either P150 or
P180 (Figures S3S and S3T). Whether the presence of these
inflammatory cells plays a key role in the subsequent develop-
ment of mPanIN lesions remains to be determined.
The Senescence Program Present in Low-Grade
mPanIN Is Abrogated during Progression to High-Grade
mPanIN Lesions
Metaplasias and low-grade mPanINs observed in mice express-
ing K-RasG12V since embryonic development display senes-
cence markers similar to those present in preneoplastic stages
of other tumor types (Collado and Serrano, 2010). However,
OIS is not an immediate consequence of K-RasG12V expression
because morphologically normal acinar cells expressing this
oncogene do not display senescence markers, regardless of
whether K-RasG12V expression takes place in embryonic or adult
acinar cells (Figure S4A; data not shown). Thus, induction of OIS
must require additional changes likely to be involved in the
acinar-ductal transdifferentiation process required to generate
low-grade mPanIN lesions. Low-grade mPanINs developing inCancerK-Ras+/G12V;p16Ink4a/p19Arflox/lox;Elas-tTA/tetO-Cre
mice not exposed to doxycycline and hence lacking
the p16Ink4a/p19Arf tumor suppressors since
embryonic development did not display senescence
markers (Figure S4B). Thus, indicating that thesetumor suppressors play a key role in the induction of senescence
in low-grade mPanIN lesions.
The senescence phenotype of these low-grade mPanINs dis-
appeared during tumor progression. As illustrated in Figure 5,
high-grade mPanIN2/3 lesions as well as mPDAC were negative
for senescence markers including endogenous senescence-
associated b-galactosidase (SA-b-Gal) and expression of the
p16Ink4a tumor suppressor. Expression of these senescence
markers inversely correlated with the appearance of proliferative
markers such as Ki67. Whereas Ki67 was expressed in <10% of
the cells in SA-b-Gal positivemPanIN1 lesions, it was detected in
>50% of the cells of high-grade mPanINs andmPDAC (Figure 5).
Pancreatitis-Induced Inflammation Contributes to
mPanIN Development
by Inhibiting OIS
Surprisingly, senescence markers were not present in low-grade
mPanINs induced by K-RasG12V expression in adult mice,
a process that requires exposure to caerulein. Thus, we decided
toascertainwhether senescencewasapropertyof lesions initiated
in the embryonic pancreas or was inhibited by caerulein-induced
pancreatitis. K-Ras+/G12V;Elas-tTA/tetO-Cre mice expressing
K-RasG12V, since late embryonic developmentwere either allowed
to develop mPanINs by themselves or were treated with caerulein
for three months. Whereas the low-grade mPanINs present in
control mice (not treatedwith caerulein) contained senescent cells
(Figures 6A–6C), none of those mPanINs present in animals
exposed to caerulein displayed senescence markers, including
SA-b-Gal and p16Ink4a (Figures 6D–6F).
As described above, the pathological features characteristic
of pancreatitis disappeared on withdrawal of caerulein. Thus,
we examined whether progressive disappearance of the in-
flammatory response had any effect on senescence. Adult
K-Ras+/G12V;Elas-tTA/tetO-Cre mice starting K-RasG12V expres-
sion at P60 were treated with caerulein for 3 months and either
immediately sacrificed or allowed to recover for 3 additional
months. Mice sacrificed at the end of the caerulein treatmentCell 19, 728–739, June 14, 2011 ª2011 Elsevier Inc. 733
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Figure 6. Senescent Low-Grade mPanINs Reappear on Partial Recovery from Pancreatitis Injury
(Left) K-Ras+/G12V;Elas-tTA/tetO-Cre mice not exposed to doxycycline, thus expressing the endogenous K-RasG12V oncogene since embryonic development
(E16.5).
(A–C) Pancreatic sections showing low-grade mPanIN1 lesions. Sections were stained for (A and B) SA-b-Gal (blue), or (C) p16Ink4a (brown) expression. (B)
Amplified version of (A) to better illustrate SA-b-Gal expression in mPanIN1 lesions.
(D–F) Pancreatic sections of mice treated with caerulein for 3months (P60 to P150) depicting low-grademPanIN1 lesions. Sections were stained for (D and E) SA-
b-Gal (blue) or (F) p16Ink4a (brown) expression. (E) Amplified version of (D) to better illustrate the absence of SA-b-Gal expression in mPanIN1 lesions.
(Right) K-Ras+/G12V;Elas-tTA/tetO-Cre mice exposed to doxycycline from conception to P60, thus expressing the endogenous K-RasG12V oncogene since P60.
(G–I) Pancreatic sections of mice treated with caerulein for 3 months (P90–P180) showing low-grade mPanIN1 lesions. Sections were stained for (G and H) SA-
b-Gal (blue) and (I) p16Ink4a (brown) expression. (H) is an amplified version of (G) to better illustrate the absence of SA-b-Gal expression in mPanIN1 lesions.
(J–L) Pancreatic sections of mice treated with caerulein for 3 months (P90–P180) and allowed to recover for 3 additional months showing low-grade mPanIN1
lesions. Sections were stained for (J and K) SA-b-Gal (blue) and (L) p16Ink4a (brown) expression. (K) Amplified version of (J) to better illustrate the reappearance of
SA-b-Gal expression in mPanIN1 lesions. Scale bars represent 50 mm (A, D, G, and J) and 20 mm (B, C, E, F, H, I, K, and L).
See also Figure S5.
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Pancreatitis Inhibits Oncogene-Induced Senescencedisplayed low-grade mPanINs devoid of senescence markers
(Figures 6G–6I). In contrast, those that were allowed to recover
for 3 months had low-grade mPanINs positive for SA-b-Gal
staining and p16Ink4a (Figures 6J–6L) as well as for PAI-1 and
Sprouty-4 expression (Figure S5A). Indeed, senescence reap-
peared as shortly as 1 month after the cessation of caerulein
exposure, a time when the inflammatory response had not
completely subsided (Figure S5B). These observations indicate
that OIS can be inhibited by limited episodes of pancreatitis
but can reappear after the pancreatitis-induced damage has
partially subsided.
Antiinflammatory Treatment Reverts Tissue Damage
andDelays Progression of Pancreatitis-InducedmPanIN
Lesions
To evaluate the overall contribution of inflammation to tumor
progression, we studied the effect of Sulindac on mPanIN/
mPDAC development. Sulindac is a nonsteroidal antiinflamma-
tory drug thought to act on COX-1 and COX-2 enzymes (Smith
et al., 1994). K-Ras+/G12V;Elas-tTA/tetO-Cre animals raised in
the presence of doxycycline until P60 were treated with caeru-
lein at P90 for 3 months. At the end of the treatment, mice
were allowed to recover for 3 additional months either without
further treatment or treated with Sulindac. Mice not exposed734 Cancer Cell 19, 728–739, June 14, 2011 ª2011 Elsevier Inc.to Sulindac displayed the typical lesions induced by pancreatitis
such as parenchyma atrophy, edema and infiltration of inflam-
matory cells (Figure 7A; Figure S6A). Moreover, their pancreata
exhibited multiple diffuse mPanIN lesions, ranging from low-
grade mPanIN1A to invasive mPDAC, although most of them
were high-grade mPanIN2/3 lesions (Figures 7A and 7B). In
contrast, mice treated with Sulindac had well-preserved pan-
creata with few areas of parenchyma atrophy and limited infiltra-
tion of inflammatory cells (Figure 7A; Figure S6B). Moreover, we
observed a dramatic reduction (75%) in the number of high-
grade lesions (Figures 7A and 7B; Figure S6B). Perhaps more
importantly, those lesions present in the Sulindac treated
animals were considerably smaller (Figures 7A and 7C; Fig-
ure S6B). Whereas the average size of the high-grade mPanINs
in control mice was 5.21 mm2, those present in Sulindac-treated
animals was only 0.14 mm2, a dramatic 95% reduction (Fig-
ure 7C). These results strongly implicate inflammation as a key
contributor to the effect of pancreatitis not only in promoting
mPanIN formation, but also in inducing progression to mPDAC.
Pancreatitis-Induced Inflammation Blocks Senescence
in Human PanINs
Finally, we examined whether some of these observations
could be extended to human patients. To this end, we
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Figure 7. Inhibition of the Inflammatory Response by Sulindac Reverts Tissue Damage and Delays Progression of mPanIN Lesions
K-Ras+/G12V;Elas-tTA/tetO-Cre mice were exposed to doxycycline until P60. At this time, doxycycline was removed from the drinking water to achieve expression
of K-RasG12V. Mice were subsequently treated with caerulein for 3 months (P90–P180). Half the mice were allowed to recover for 3 months without further
treatment whereas the other half was treated with Sulindac.
(A) H&E-stained paraffin sections of representative pancreata of mice (left) not treated or (right) treated with Sulindac. Note that the pancreata of the untreated
mice displayed high levels of edema, fibrosis, parenchyma atrophy, and abundant large mPanIN lesions. In contrast, mice that underwent Sulindac treatment
showed a well-preserved parenchyma and contained few small mPanINs. Arrowheads point to mPanIN lesions, (i) indicates an islet. Scale bar represents 50 mm.
(B) Average lesions per mouse. Solid bars indicate mice not treated with Sulindac (n = 3). Open bars correspond to mice treated with Sulindac (n = 3). Data shown
represent mean ± SD. ***p < 0.00017, *p < 0.036.
(C) Area of mPanIN1, mPanIN2/3 and mPDAC lesions observed in serial pancreata sections. Solid bars indicate mice not treated with Sulindac (n = 3). Open bars
correspond to mice treated with Sulindac (n = 3). Data shown represent mean ± SD. **p < 0.0037, ***p < 0.00012.
See also Figure S6.
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Pancreatitis Inhibits Oncogene-Induced Senescenceexamined the expression of P16INK4a as a marker of senes-
cence in samples obtained from pancreata of six patients
with PDAC that also contained low-grade PanINs. Whereas
none of the cells within the PDAC expressed detectable levels
of this tumor suppressor, all six low-grade PanINs presented
a very strong nuclear signal when probed with anti P16INK4a
antibodies (Figure 8A). Parallel analysis of Ki67 staining,
a marker for proliferation, revealed an inverse correlation with
P16INK4a immunostaining (Figure 8C), an observation highly
reminiscent of the results obtained in mice. These findings indi-
cate that human low-grade PanINs also contain senescent
cells.
Next, we examined the presence of senescent cells in PanINs
present in surgically removed samples from nine patients
suffering from chronic pancreatitis. The clinical histories of these
patients are summarized in Table S1. To our surprise, low-grade
PanINs were strongly positive for P16INK4a expression only in
four of the nine samples (Figure 8B). Examination of the clinical
history of these patients revealed that the four patients whose
samples displayed senescence markers had received antiin-
flammatory treatments. Whereas two of them had been treatedwith prednisolone, the other two had received NSAIDs. In
contrast, none of the five patients that lacked of P16INK4a
expression had received antiinflammatory therapy (Figure 8B;
Figure S7). These pancreatitis-derived biopsies also displayed
significant differences when they were analyzed for Ki67 expres-
sion. As illustrated in Figure 8C, PanINs present in biopsies
derived from pancreatitis patients that have received antiinflam-
matory treatment were essentially negative for Ki67. In contrast,
those PanINs present in biopsies derived from untreated
patients contained high levels of Ki67. These results strongly
suggest that inhibition of the inflammatory response induced
by pancreatitis helped to maintain senescence, possibly
contributing to the clinical benefit provided by antiinflammatory
drugs.
DISCUSSION
Most cancers arise from somatic mutations during adulthood.
Thus, proper understanding of how tumors are initiated requires
modeling cancer in adult animals. In pancreas, the susceptibility
to transformation by a resident K-Ras oncogene displayed byCancer Cell 19, 728–739, June 14, 2011 ª2011 Elsevier Inc. 735
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Figure 8. Senescence Markers in Human Low-Grade PanINs
(A) Low-grade PanINs present in biopsies from PDAC patients display
senescence markers. (Left) Sections showing low-grade PanIN1s are positive
for P16INK4a immunostaining. (Right) Sections depicting PDAC lesions are
negative for P16INK4a immunostaining. Insets show amplified images to
illustrate nuclear staining in PanIN1 lesions. Scale bar represents 50 mm.
(B and C) Antiinflammatory treatment restores senescence in low-grade PanIN
of chronic pancreatitis patients. (B) P16INK4a immunostaining of biopsies
obtained from patients suffering from chronic pancreatitis. (Left) Represen-
tative section displaying low-grade PanIN1s positive for P16INK4a staining
present in a biopsy obtained from a patient treated with antiinflammatory
drugs. (Right) Representative section displaying low-grade PanIN1s negative
for P16INK4a staining present in a biopsy obtained from a patient not-treated
with antiinflammatory drugs. Insets show amplified images to illustrate nuclear
staining in PanIN1 lesions. Scale bar represents 50 mm. (C) Quantification of
the percentage of cells present in low-grade PanIN1 lesions positive for (open
bars) P16INK4a immunostaining or (solid bars) Ki67 staining. Samples were
obtained from (left) PDAC patients, (center) chronic pancreatitis patients
treated with antiinflammatory drugs, and (right) chronic pancreatitis patients
not treated with antiinflammatory drugs. Data shown represent mean ± SD.
See also Figure S7 and Table S1.
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Pancreatitis Inhibits Oncogene-Induced Senescenceembryonic pancreatic precursors is lost in adult mice (p R 60)
(Guerra et al., 2007). Indeed, the resistance of the adult pancreas
to malignant transformation extends beyond K-Ras oncogenic736 Cancer Cell 19, 728–739, June 14, 2011 ª2011 Elsevier Inc.signaling. As illustrated here, adult acinar cells are also refractory
to transformation by concomitant expression of a resident K-Ras
oncogene and loss of the p16Ink4a/p19Arf or Trp53 tumor
suppressors, some of the most robust mutational events known
in cancer.
In spite of their resistance to mutational insults, adult acinar
cells retain their capacity to proliferate in response to certain
pathological insults and to acquire tumorigenic properties (Slater
et al., 1998; Jura et al., 2005). Exposure of adult mice to caeru-
lein-induced pancreatitis induces proliferation of their acinar
cells in order to repair tissue damage but does not result in
formation of mPanINs or other preneoplastic lesions (Strobel
et al., 2007). However, caerulein treatment restores permissive-
ness of adult acinar cells to malignant transformation by K-Ras
oncogenes (Guerra et al., 2007; Gidekel Friedlander et al.,
2009; Morris et al., 2010). Additional loss of the p16Ink4a/
p19Arf or Trp53 (unpublished results) tumor suppressors exac-
erbates the transformation process. Interestingly, pancreatitis
does not cooperate with loss of either of these tumor suppres-
sors. Thus, indicating that K-Ras oncogenes are essential for
initiation of mPDAC.
mPDACs generated by a combination of oncogenic insults
including K-Ras oncogenes, loss of p16Ink4a/p19Arf or Trp53,
and caerulein-induced pancreatitis often display invasive and
metastatic properties, albeit those induced in adult animals
require longer latencies (Aguirre et al., 2003; Hingorani et al.,
2005; Guerra et al., 2007). Moreover, a combination of K-Ras
oncogenes and loss of p16Ink4a/p19Arf in early pancreatic
precursors (Aguirre et al., 2003) or in embryonic acinar cells
(this study) frequently result in anaplastic carcinomas, an
aggressive tumor type seldom observed when these mutations
are induced in adult animals. These results suggest that tumors
that originate in the embryo develop more aggressively than
those initiated during adulthood. Moreover, the more frequent
occurrence of anaplastic carcinomas suggests that these onco-
genic insults may engage pathways in embryonic acinar cells
that are downregulated in their adult counterparts.
In humans, chronic pancreatitis represents one of the highest
risk factors for developing PDAC (Lowenfels et al., 1993).
However, most PDAC patients do not have a history of chronic
pancreatitis. Thus, it is important to determine whether less
aggressive forms of pancreatitis, including sporadic or even
asymptomatic pancreatitis, may also increase the risk of devel-
oping PDAC. As illustrated here, limited bouts of mild pancrea-
titis lasting as little as 1 month were sufficient to elicit mPanIN
formation, providing that the injured acinar cells expressed
a K-Ras oncogene. Longer pancreatitis events resulted in
increased incidence of mPanIN formation along with the appear-
ance of high-grade mPanIN lesions and mPDAC with reduced
latencies. The number and size of the lesions observed in these
two protocols were considerably lower than those observed in
mice suffering from chronic pancreatitis (Guerra et al., 2007).
Finally, mPDAC can also develop if pancreatitis occurs before
activation of K-Ras oncogenes, providing that tissue damage
and the inflammatory response have not subsided. These obser-
vations raise the possibility that PDAC development in humans
may also stem from limited bouts of pancreatitis providing that
tissue repair and the inflammatory response coexist with
sporadic K-Ras mutations.
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Pancreatitis Inhibits Oncogene-Induced SenescencePancreatitis, most likely through its inflammatory component,
contributes to mPanIN progression by abrogating OIS, a natural
defense mechanism against tumor development (Collado and
Serrano, 2010). Postmortem analysis of pancreatic tissue ob-
tained from autopsies of healthy individuals has revealed the
presence of PanIN lesions carrying K-Ras oncogenes that,
presumably had not progressed to PDACdue to an active senes-
cence program (Terhune et al., 1998; Lu¨ttges et al., 1999; Lo¨hr
et al., 2005). Low-grade mPanIN lesions induced in the embry-
onic pancreas do not display senescence markers if the mice
suffered from pancreatitis. In adult animals, which require
pancreatitis for mPanIN development, senescence markers
can only be detected once the inflammatory response has
subsided. These observations suggest that one of the mecha-
nisms by which pancreatitis-induced inflammation contributes
to the progression of mPDAC is by eliminating the senescence
barrier that prevents progression of low-grade mPanINs into
more aggressive lesions.
In addition, the inflammatory response delays repair of the
nontransformed pancreata and stimulate expansion of mPanIN
lesions. Whether the latter effect is solely mediated by inhibiting
senescence, remains to be determined. Animals treated with the
dual COX-1/2 inhibitor Sulindac for 3 months after exposure to
caerulein displayed almost normal pancreata with only few areas
of atrophy and limited numbers of inflammatory cells. Whereas
Sulindac had limited effect on the number of low-grade lesions,
it caused a significant reduction (up to 75%) in the number of
high-grade mPanINs and mPDAC. Yet, the most dramatic effect
of this antiinflammatory treatment was observed on the extent of
the area occupied by mPanIN lesions, which displayed
a dramatic 95% reduction. These observations suggest that, in
addition to eliminating the senescence barrier, the inflammatory
response induced by episodic pancreatitis may contribute to
mPDAC development by additional mechanisms.
How relevant are these observations to human patients? As
illustrated in this study, low-grade PanINs present in samples
surgically removed from PDAC patients displayed senescence
markers. No such markers were observed in pancreatic tumor
cells. Yet, the most informative observations correlating PanIN
development with senescence came from the analysis of
samples surgically removed from chronic pancreatitis patients.
Although the number of samples analyzed is still small, we found
an intriguing correlation between the occurrence of senescence
in low-grade PanINs and prior exposure of the patients to antiin-
flammatory agents. The results were independent of whether the
antiinflammatory treatment was based on steroids or on
NSAIDs. These observations suggest that pancreatitis patients
may benefit from antiinflammatory treatments by retaining the
senescent phenotype in their low-grade PanIN lesions, possibly
preventing their progression into high-grade lesions.
K-RAS mutations have been identified in the pancreas of
healthy individuals (Terhune et al., 1998; Lu¨ttges et al., 1999;
Lo¨hr et al., 2005). In addition, patients with chronic pancreatitis
have over 10-fold increased risk of developing PDAC (Lowenfels
et al., 1993; Malka et al., 2002). As illustrated in this study,
mPDAC develop in adult mice expressing a resident K-Ras
oncogene if they undergo episodic events of pancreatitis, even
under asymptomatic conditions. These observations raise the
possibility that in humans, at least some PDACs may originatefrom mild bouts of pancreatitis in individuals that unknowingly
carry K-RAS mutations. Because the identification of K-RAS
oncogene containing cells within the pancreas of healthy individ-
uals is not possible, it will be important to monitor people that
have been diagnosed with pancreatitis for the development of
pancreatic lesions, that if unattended may lead to PDAC. Like-
wise, it will be important to develop biomarkers that can identify
individuals that have suffered from asymptomatic pancreatitis,
at least in high-risk populations.
The correlation between inflammation and loss of OIS also
has important implications for the prevention of PDAC develop-
ment. Treatment with antiinflammatory drugs maintained
senescence markers in low-grade PanINs present in chronic
pancreatitis patients. Interestingly, recent epidemiological
studies have suggested a beneficial correlation between
NSAIDs and pancreatic cancer risk (Bonifazi et al., 2010;
Bradley et al., 2010; Rothwell et al., 2011). Our results suggest
that antiinflammatory treatments might decrease the risk of
PDAC development by maintaining the senescence phenotype
of early PanIN lesions. Now, it will be necessary to determine
whether inhibition of the inflammatory response will have
a beneficial response in patients already carrying fully devel-
oped PDAC. The mouse models utilized here should contribute
to address this question.
EXPERIMENTAL PROCEDURES
Mice
K-Ras+/LSLG12Vgeo;Elas-tTA/tetO-Cre (Guerra et al., 2007), p16Ink4a/
p19Arflox/lox (Krimpenfort et al., 2001), and Trp53lox/lox (Jonkers et al., 2001)
strains have been described. All experiments were approved by the CNIO
Ethical Committee and performed in accordancewith the guidelines for Ethical
Conduct in the Care and Use of Animals as stated in The International Guiding
Principles for Biomedical Research involving Animals, developed by the
Council for International Organizations of Medical Sciences (CIOMS).
Human Samples
Human samples were obtained from the histopathology files of University
College Hospital from patients who had undergone pancreatoduodectomy,
distal pancreatectomy or total pancreatectomy with a primary diagnosis of
chronic pancreatitis or ductal adenocarcinoma from 2004 to 2008 after
approval by the institutional Research Ethics Committee (Central London
REC 3, Reference 06/Q0512/106) and informed consent was obtained from
all patients.
Histopathology and Immunohistochemistry
Specimens were fixed in 10% buffered formalin and embedded in paraffin. For
histopathological analysis, pancreata were serially sectioned (3 mm) and every
10 sections stained with hematoxylin and eosin. Remaining sections were kept
for immunohistochemical studies. Antibodies used for mouse samples include
CD3 (1/250, goat polyclonal, Santa Cruz 1127), Cytokeratin19 (rat monoclonal,
Troma III, Developmental Studies Hybridoma Bank), Chymotrypsin
(1/50, mouse monoclonal 4E1, ABD Serotec, 2100-0657), Elastase (1/50,
rabbit polyclonal, ABCAM, ab21590), F4/80 (1/25, rat monoclonal BM8,
BMA Biomedicals), Ki67 (prediluted rabbit monoclonal SP6, Master Diagno´s-
tica 0003110QD), MPO (1/1250, rabbit polyclonal, DAKO A0398), PAI-1 (1/50,
rabbit polyclonal, Santa Cruz sc-8979), Pax5 (1/500, goat polyclonal, Santa
Cruz 1974), phospho-Histone H3-Ser10 (1/200, rabbit polyclonal, MILLIPORE
06-570), prosurfactant protein C (SPC) (1/50, rabbit polyclonal, MILLIPORE
AB3786), p16Ink4a (1/75, rabbit polyclonal, Santa Cruz 1207), Sox9 (1/800,
rabbit polyclonal, MILLIPORE AB5535), and Sprouty-4 (1/50, goat polyclonal,
Santa Cruz 18607) antibodies. Antibodies against Pdx1 were kindly provided
by A. Skoudy. Positive cells were visualized using 3,3-diaminobenzidine tetra-
hydrochloride plus (DAB+) as a chromogen. For human samples, P16INK4aCancer Cell 19, 728–739, June 14, 2011 ª2011 Elsevier Inc. 737
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Pancreatitis Inhibits Oncogene-Induced Senescenceimmunolabeling was performed according to the manufacturer’s protocol
(CINtec Histology Kit, mtmlabs, Heidelberg, Germany). Ki67 staining was
performed with mouse monoclonal Anti-Human Ki-67 (Dako).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures and one table and can be found with this article online at
doi:10.1016/j.ccr.2011.05.011.
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